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ORIGINAL ARTICLE
Inflammatory genes TNFα and IL6 display no signs of
increased H3K4me3 in circulating monocytes from untreated
rheumatoid arthritis patients
TC Messemaker1,2, HMM Mikkers2, TW Huizinga1, REM Toes1, AHM van der Helm- van Mil1 and F Kurreeman1
Innate immune cells, such as monocytes, can adopt a long-lasting pro-inflammatory phenotype, a phenomenon called ‘trained
immunity’. In trained immunity, increased cytokine levels of genes, like interleukin (IL)-6 and tumor necrosis factor (TNF)-α, are
observed, which are associated with increased histone 3 lysine 4 trimethylation (H3K4me3) in the promoter region. As systemic IL6
and TNFα levels are increased in rheumatoid arthritis (RA) patients and monocytes are known to be the primary producers of TNFα
and IL6, we hypothesized that ‘trained immunity’ signals may be observed at these genes in monocytes from RA patients. CD14+
monocytes were isolated from untreated RA patients and paired age-matched healthy controls. H3K4me3, mRNA, protein and
serum levels of IL6 and TNFα were evaluated by chromatin immunoprecipitation, reverse-transcription quantitative PCR and
enzyme-linked immunosorbent assays. Despite elevated serum levels of TNFα and IL6 in the tested RA patients (Po0.05), ex vivo
isolated monocytes displayed similar H3K4me3 levels to healthy controls in the promoter region of TNFα and IL6. Concordantly,
mRNA and protein levels of IL6 and TNFα were similar before and after lipopolysaccharide stimulation between patients and
controls. Together, with the current number of individuals tested we have not detected enhanced trained immunity signals in
circulating monocytes from untreated RA patients, despite increased IL6 and TNFα serum levels.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease mainly
characterized by inflammation of the joints. Although some
effective treatment of RA exists, many factors that lead to the
development of the disease remain unknown. Both environmental
and genetic factors have been shown to have a role in the onset
of the disease.1 For many diseases, including those of auto-
immune nature, environmental triggers are thought to influence
gene regulation via changes in the epigenetic landscape.2,3
Epigenetic changes are defined by non-genetic changes in gene
activity, which are influenced by various factors including the
following: non-coding RNAs, DNA methylation and histone
modifications.4,5 In innate immune cells as well, environmental
triggers were shown to induce long-lasting epigenetic changes
described in a concept known as ‘trained immunity’.6 In the study
from Quintin et al.,6 monocytes were pre-exposed to β-glucan (a
cell-wall component of Candida albicans) for 24 h, which resulted
in changes of the epigenetic landscape. One of the identified
hallmarks of trained immunity was an induction of histone 3 lysine
4 trimethylation (H3K4me3) in the promotor region of immune
genes like tumor necrosis factor (TNF)-α and interleukin (IL)-6, an
indicative mark for active promoters.6,7 As a result of increased
H3K4me3 levels, a second immune stimulation of these pre-
exposed monocytes resulted in an increased immune response
shown initially by elevated IL6 and TNFα levels.6 These results
indicated that innate immune cells like monocytes can acquire
long-lasting alterations in the epigenetic landscape resulting in
the enhanced production of cytokines.
In RA, TNFα and IL6 are elevated in the serum and synovium of
patients compared with healthy individuals.8 Moreover, both anti-
TNFα treatment and anti-IL6 treatment are currently successful
therapies against RA, suggesting the importance of both cytokines
in disease pathogenesis.9 As monocytes can produce high levels
of TNFα and IL6, we hypothesized that changes in H3K4me3 of
monocytes might exist in early untreated RA patients, thereby
contributing to enhanced cytokine levels and thus to the disease
pathogenesis of RA.10 To our knowledge, this is the first report
measuring H3K4me3 levels in the promoter region of two RA-
relevant cytokines in primary immune cells.
RESULTS
Detection of differences in H3K4me3 levels in the promoter of IL6
and TNFα in human monocytes
In order to test our hypothesis and to show that in our hands
monocytes can obtain a trained phenotype, we repeated the
previously published trained immunity model as described by
Quentin et al.6 Monocytes from healthy donors were pre-
incubated with β-glucan for 24 h followed by a 6-day resting/
refreshing period. After 7 days, H3K4me3, protein and RNA levels
of TNFα and IL6 from these monocytes were compared with
monocytes, which were not exposed to β-glucan from the same
donor. We observe similar effects with a ~ 2-fold increase in
H3K4me3 levels at the TNFα and IL6 promoter regions with a
concurrent increase in RNA and cytokine levels (Supplementary
Figure S1). We next calculated how many RA patients and
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matched healthy controls we would require to detect similar effect
sizes. A total sample size of four is required, two RA patients and
two healthy controls, providing 80% to detect a significant
difference at Po0.05.
Similar H3K4me3 levels on the IL6 and TNFα promoter in
monocytes from RA patients and healthy controls
To minimize sources of variation between patients and controls,
we simultaneously collected blood and serum from RA patients
and age-matched healthy individuals (Figure 1 and Supplemen-
tary Figure S2). RA patients display significantly higher IL6 and
TNFα levels in serum as compared with controls, indicating that
in vivo differences in cytokine levels are present (Supplementary
Figure S3). In order to measure H3K4me3 levels, CD14+
monocytes were directly isolated and H3K4me3 levels of TNFα
and IL6 were simultaneously measured. However, H3K4me3 levels
on the promoter region of TNFα and IL6 were similar in untreated
RA patients and healthy controls (Figures 2a and b, left panel,
P= 0.61 for both genes). The observed content of H3K4me3 from
our experiments coincide with previously measured H3K4me3
chromatin immunoprecipitation (ChIP)-sequencing levels in
healthy individuals derived from publicly available data from
ENCODE/broad institute (Figures 2a and b, right panel). H3K4me3
levels of housekeeping gene RPL5 were similar between untreated
RA patients and healthy controls, and correcting for RPL5 as an
additional internal control did not alter the H3K4me3 levels
between healthy controls and untreated RA patients
(Supplementary Figure S4A and B). Finally, Insulin, which is not
expressed by monocytes, was used as a negative control and did
not display H3K4me3 levels in monocytes as expected
(Supplementary Figure S4C).
Similar IL6 and TNFαmRNA and protein levels, and responsiveness
of monocytes from RA patients and healthy controls
To confirm our histone trimethylation results and further confirm
that both monocytes from RA patients and healthy controls
respond similarly, we evaluated RNA levels of TNFα and IL6 before
and after lipopolysaccharide (LPS) stimulation. In unstimulated
monocytes we observed low levels of TNFα and IL6 that were
similar in controls and RA patients (Supplementary Figure S5).
Figure 1. Flowchart of technical procedure isolating monocytes from healthy controls and untreated RA patients. Blood was obtained from a
newly diagnosed untreated RA patient and a healthy control on the same day and used for PBMCs isolation. After a paired PBMC isolation,
CD14+ monocytes were isolated by magnetic beads and used for (i) purity check by fluorescence-activated cell sorting, (ii) DNA-Histone
crosslinking and stored at − 80 °C for ChIP experiments or (iii) RNA and protein analysis by culturing the isolated monocytes in presence of
RPMI (unstimulated) or LPS.
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Upon stimulation, a strong induction of expression was observed
in both healthy controls and RA patients for TNFα and IL6
(Figures 3a and b). Again, similar RNA levels between both groups
were observed for IL6 (RA: 42637 ± 19208 vs controls:
47996 ± 38235; P= 0.70) and TNFα (RA: 78.5 ± 20.9, controls:
83.5 ± 42.3; P= 0.9). In addition, we investigated cytokine levels
in the supernatant of unstimulated and LPS-stimulated mono-
cytes. Similar protein levels were observed in the supernatant of
monocyte cultures obtained from the two groups (Figures 3c and
d), although TNFα and IL6 levels seemed slightly elevated in RA
patients after LPS-stimulation (TNFα concentration: RA:
4.3 ng ml− 1 ± 2.9 vs controls: 2.8 ng ml− 1 ± 2.6; P= 0.40); IL6
concentrations: RA: 67.2 μg ml− 1 ± 14.6 vs controls: 50.8 μg ml− 1
± 17.3; P= 0.19). In addition, dividing patients on basis of
autoantibody status (anti-citrullinated protein antibody positivity)
revealed neither differences in IL6 and TNFα production
(Supplementary Figure S6). Together, these findings suggest that
there are no substantial differences regarding H3K4me3, mRNA
levels or cytokine levels of IL6 and TNFα between circulating
monocytes from RA patients and healthy controls in this study.
DISCUSSION
In this study we aimed to measure H3K4me3 levels in the
promotor regions of TNFα and IL6, in ex vivo primary monocytes
from RA patients and healthy individuals. TNFα and IL6 are
important cytokines for the pathogenesis of RA and can both be
found in large abundances in the joints of RA patients.11,12 IL6 can
activate several cell types and is involved in the maturation of B
cells and thus the production of autoantibodies.13 TNFα is a
potent inducer of other inflammatory genes and inhibition of
either TNFα or IL6 have both been shown to be effective for
treatment of RA.14,15 Monocytes are the primary producers of IL6
and TNFα and ‘trained’ monocytes have been shown to have
enhanced production of both cytokines. In order to test whether
monocytes from RA patients display different epigenetic patterns
at these two genes, a rigorous protocol of collection of blood and
isolation of monocytes from both RA patients and paired age-
matched healthy controls was implemented. To our knowledge,
this is the first time that a study addressing epigenetic changes in
ex vivo primary monocytes from early untreated RA patients has
been performed.
Epigenetic modifications have a crucial role in regulating gene
expression.16 The role of DNA methylation and histone modifica-
tions have both been studied in relation to RA.17 In synovial
fibroblast, structural changes in DNA methylation correlate with
fibrotic development in the joint of RA patients.18 In several
immune cells as well, changes were observed in the DNA
methylation of relevant immune-related genes, for example,
hypomethylation of IL6 in B cells of RA patients19 or hypomethyla-
tion of CD40LG in CD4+ T cells.20 Furthermore, expression levels of
various histone-modifying enzymes have been investigated in RA.
EZH2 (Enhancer of Zeste Homolog 2), a histone methyl transferase
was found elevated in synovial fibroblast from RA patients.21
However, studies evaluating changes in histone methylation in
patients with autoimmune diseases are scarce. In this study, we
Figure 2. H3K4me3 levels in monocytes from healthy controls and untreated RA patients. (a) H3K4me3 levels of the IL6 promoter in healthy
controls (controls) and untreated RA patients (RA) (top). The y axis represents the percentage of precipitated H3K4me3 normalized for DNA
input. H3K4me3 occupancy of the IL6 promoter in healthy individuals measured by ChIP-sequencing (ChIP-seq) from ENCODE/Broad institute
(bottom). (b) H3K4me3 levels of the TNFα promoter in healthy controls (controls) and untreated RA patients (RA) (top). H3K4me3 occupancy of
the TNFα promoter in healthy individuals measured by ChIP-seq from ENCODE/Broad institute (bottom). Mann–Whitney U-test was used to
test for significant differences.
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evaluated for the first time H3K4me3 levels on the promoter of
two important cytokine genes in monocytes directly isolated from
RA patients.
Although many types of histone modifications are known,
H3K4me3 was shown to correlate with higher TNFα and IL6 levels
in β-glucan-trained monocytes and was therefore used as a
marker for trained immunity. Here we report that although we can
reliably measure twofold differences in H3K4me3 levels between
β-glucan-trained and untrained monocytes, our study was
sufficiently powered to detect effect size differences as low as
1.8; however, such epigenetic differences on the H3K4me3 mark
between RA patients and healthy controls were not observed. This
finding was confirmed by RNA and protein levels of IL6 and TNFα,
which had similar levels in RA patients and healthy controls after
LPS stimulation. These results indicate that RA monocytes are
likely not in a continuous pro-inflammatory ON-state at the IL6
and TNFα genes on basis of the H3K4me3 levels and LPS
responsiveness. Although we demonstrate that in vitro trained
monocytes have similar time-response dynamics in their cytokine
production as untrained monocytes (Supplementary Figure S7),
we cannot exclude that RA-specific differences in cytokine
dynamics exist. It is probable that RA monocytes produce higher
TNFα and IL6 levels in vivo via other mechanisms as the possibility
exists that RA monocytes will stay activated longer compared to
healthy controls and such effects will be missed in our study due
to the chosen time points and LPS concentration. Moreover, in our
study, monocytes were obtained from peripheral blood and we
cannot exclude that locally activated monocytes in the joints of RA
patients show changes in their epigenetic landscape. Besides
monocytes other RA-relevant cells types are capable of producing
TNFα and/or IL6. These cell types include T cells, B cells, mast cells,
synovial fibroblasts and osteoblasts, and may also contribute to
the induced TNFα and IL6 levels in the serum of patients.22 It
would be interesting to investigate whether these cell types can
also obtain a trained epigenetic landscape and whether this
contributes to development of RA.
Besides changes in H3K4me3 upon immune stimulation, other
histone marks such as H3K4me1 and H3K27Ac have more recently
been described to shape the trained immunity epigenetic
landscape.23 In line with these findings, latent enhancers also
acquire changes in H3K4me1, H3K4me3, H3K27Ac and PU.1
binding upon immune triggering.24,25 These studies illustrate the
complexity of the epigenetic landscape that is formed upon
different immune stimuli and suggests that further in-depth
studies may be required. Nonetheless, epigenetic changes are
currently being used for diagnostics and therapy in other diseases
(reviewed in ref. 26). In RA as well, an inhibitor of histone-modifying
enzyme was suggested as an inflammatory suppressor.27 Gillespie
et al.27 showed that RA peripheral blood mononuclear cells
(PBMCs) possess increased histone deacetylase activity and
inhibition of this class of enzymes could reduce the production
of both TNFα and IL6 in a compound and cell-type-dependent
manner.27 However, PBMCs are a collection of diverse cell types
and results obtained represent an average across all cells. These
data highlight the complexity and variety of factors that can
influence the epigenetic landscape. Investigating the epigenetic
landscape in disease pathology is thus influenced by these factors
and the outcome of results may rely on (i) the histone
modification that is being studied, (ii) the genes investigated
and (iii) the choice of cell type. Currently, our results indicate that
Figure 3. RNA and protein levels of IL6 and TNFα in monocytes from healthy controls and RA patients. RNA levels of IL6 (a) and TNFα (b) were
determined for unstimulated (− ) and LPS-stimulated (+) monocytes isolated from healthy controls and untreated RA patients. RNA levels were
normalized for GAPDH and B2M as housekeeping genes. The sample with the lowest expression was set to 1. Protein concentrations of IL6 (c)
and TNFα (d) were measured in the supernatant of unstimulated (− ) and LPS-stimulated (+) monocytes isolated from healthy controls and
untreated RA patients. The concentration of LPS added was 10 ng ml−1. Mann–Whitney U-test was used to test for significant differences.
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large differences between circulating monocytes isolated from RA
patients and healthy individuals are absent in context of TNFα and
IL6 levels. However, we cannot exclude that more subtle
differences may be detected in larger sample sizes. In conclusion,
with the current number of individuals tested we have not
detected evidence that H3K4me3 levels at two immune relevant
genes IL6 and TNFα are enhanced in RA. Further studies
addressing genome-wide patterns of epigenetic changes in larger
numbers of individuals may yield additional insight into whether




Patients fulfilling the 1987 criteria for RA28 recruited from the rheumato-
logic outpatient clinic of the Leiden University Medical Center were
included in this study. Patients were studied at the time of diagnosis and
before disease-modifying antirheumatic drugs (including no corticoster-
oids) were started. Age-matched healthy controls were also included, and
were preferably healthy partners or family member of the patients. This
study was approved by the ethical committee of the Leiden University
Medical Center and all patients and healthy donors provided written
informed consent. Serum from patients and healthy controls was obtained
by incubation of blood at room temperature for 30 min followed by
centrifugation at 2000 g for 10 min. Supernatant (serum) was transferred
and stored at − 80 °C until Illuminex measurements. PBMCs isolations were
performed from an untreated RA patient and a matched healthy control
and were performed on the same day in a paired manner, with the
exception one RA patient, which did not have a paired control. PBMC
isolations were performed from eight untreated RA patients (seven
females, one male mean± s.d. age 59.3 ± 11.2 years) and seven healthy
controls (five females, two males; age 51.6 ± 10.9 years). Four patients were
positive for anti-citrullinated protein antibodies and five patients were
positive for rheumatoid factor. More detailed characteristics can be found
in Supplementary Table S1.
Cell culture
PBMCs from healthy controls and RA patients were isolated on a Ficoll
gradient (Pharmacy LUMC, Leiden, The Netherlands). CD14+ monocytes
were isolated using magnetic beads and cultured as previously
described.29 Cells were either crosslinked for ChIP experiments and/or
cultured for RNA and protein measurements. For the ChIP experiment,
seven RA patients and six healthy controls were used. For seven RA
patients and five healthy controls, enough cells were obtained from
CD14+ isolation and additional RNA and protein analysis was performed.
RNA was isolated 4 h after stimulation with either LPS or RPMI
(unstimulated). Supernatant was collected 20 h after stimulation with
LPS or from unstimulated monocytes and used for enzyme-linked
immunosorbent assay to measure the level of secreted cytokines. β-
Glucan stimulation was performed as described by Quintin et al.6 In short,
CD14+ isolated monocytes were once pre-incubated for 24 h with either β-
glucan (Invivogen, San Diego, CA, USA) from Alcaligenes faecalis
(10 μg ml− 1) or RPMI medium (unstimulated). After 24 h, β-glucan was
removed by refreshing with new medium without β-glucan and was
continued to be refreshed every 2 days over a 6-day period. After 7 days
(1 day β-glucan, 6 day washing/refreshing), monocytes were either
used for chromatin immune precipitation or stimulated with LPS
(10 ng ml− 1) and RPMI (unstimulated) for RNA and protein analysis.
Viability of monocytes after 7 days of culturing was monitored by
a LUNA-II automated cell counter (Logos Biosystems, Villeneuve d’Ascq,
France).
Chromatin immunoprecipitation
For ChIP, 1.5 × 106 monocytes were crosslinked in 1% formaldehyde
(Mallinckrodt-Baker, Dublin, Ireland) for 10 min, treated with 1/10 volume
of 1.25 M glycine (J.T.Baker, Thermo Fisher, Waltham, MA, USA) for 3 min,
washed with ice-cold phosphate-buffered saline and stored in − 80 °C after
snap freezing. Crosslinked monocytes were lysed using 1% SDS and 20 mM
HEPES, and sonicated using a Biorupter sonication device (Diagnode,
Seraing, Belgium). Chromatin sonication (DNA fragments between 150–
600 bp) was validated by agarose gel electrophoresis. Sonicated chromatin
was divided into two fractions and used as either input material or for
overnight H3K4me3 precipitation using protein G dynabeads (Life
Technologies, Oslo, Norway) and polyclonal H3K4me3 antibody (Catalog
number C15410003-010, Diagnode). DNA was isolated by de-crosslinking
input DNA and H3K4me3 precipitated DNA in elution buffer (1% SDS, 0.1 M
NaHCO3, 0.19 M NaCl, 2 units Prot K (Thermo Scientific)) at 65 °C for 4 h
followed by phenol/chloroform DNA precipitation. Quantification of
immunoprecipitated DNA was performed by quantitative PCR using
primers provided in Supplementary Table S2. Primers were located in
the promotor regions of IL6, TNFα and RPL5 as shown by H3K4me3
containing regions in monocytes via publicly available ChIP-sequencing
data obtained from ENCODE/Broad institute (GEO accession:
GSM1003536). Insulin, which is not expressed by monocytes, was used
as negative control.
RNA isolation, cDNA synthesis and expression analysis
RNA isolation and cDNA synthesis was performed as previously
described.29 Two housekeeping genes were used for normalization:
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-2 microglo-
bulin (B2M). Relative expression was calculated using the ΔΔCT method.30
The sample with the lowest expression was set to 1. Primer sequences are
listed in Supplementary Table S2. Before quantitative PCR, minus RT
samples were checked for genomic DNA contamination.
Cytokine production
TNFα and IL6 levels in the medium of cultured monocytes were measured
using human TNF ELISA kit (BD Bioscience, San Jose, CA, USA) or human IL6
DuoSet ELISA (R&D System, Abingdon, UK), respectively. TNFα and IL6 in
serum were determined using the Milliplex Human Adipocyte panel
(Millipore, Amsterdam, The Netherlands) and measured on the Bio-Plex
array reader and Bio-Plex software in accordance with the manufacturer’s
instructions.
Statistical analysis
Data are presented as means ± s.d. Statistical analysis was performed using
GraphPad (GraphPad, San Diego, CA, USA). Mann–Whitney U-test was
performed to determine significant differences. Differences with P-values
o0.05 were considered statistically significant. Sample size calculation was
performed based on the observed effect size in β-glucan-trained
monocytes using G power v3.1 (University of Düsseldorf, Germany).
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